Your browser doesn't support javascript.
loading
Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy.
Marinò, Michele; Dottore, Giovanna Rotondo; Leo, Marenza; Marcocci, Claudio.
Afiliação
  • Marinò M; Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy.
  • Dottore GR; Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy.
  • Leo M; Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy.
  • Marcocci C; Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy.
Horm Metab Res ; 50(12): 887-893, 2018 Dec.
Article em En | MEDLINE | ID: mdl-30096720
ABSTRACT
Based on the role of oxidative stress in the pathogenesis of Graves' hyperthyroidism and Graves' orbitopathy, the use of the antioxidant agent selenium has been proposed and several studies on the subject have been conducted, both in vitro and in vivo. Whereas a true benefit related to the use of selenium in patients with Graves' hyperthyroidism has been questioned, its use in patients with mild Graves' orbitopathy is generally believed to be beneficial because of which selenium has entered in the clinical practice for this eye condition.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Selênio / Oftalmopatia de Graves Limite: Humans Idioma: En Revista: Horm Metab Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Selênio / Oftalmopatia de Graves Limite: Humans Idioma: En Revista: Horm Metab Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália